Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is proud to announce its latest AI-powered research advancement, published on European Journal of Medicinal Chemistry, ACS Medicina (IMAGE)

InSilico Medicine

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is proud to announce its latest AI-powered research advancement, published on European Journal of Medicinal Chemistry, ACS Medicina

Caption

With the aid of Pharma.AI, Insilico’s proprietary AI platform for drug discovery and scientific research, the Insilico scientists have unveiled a series of potent and selective HPK1 inhibitor series for immunotherapy, each with better druggability potential compared to the previous one.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.